ChromaDex (CDXC:NASDAQ) Investor Relations Material

Overview

ChromaDex Corporation, a leading bioscience company developing products for healthy aging, operates through three segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The company's innovative research on nicotinamide adenine dinucleotide (NAD+) has led to the development and commercialization of proprietary-based ingredient technologies, including its flagship ingredient, NIAGEN. ChromaDex also offers finished dietary supplements containing its proprietary ingredients to consumers and distributors, as well as raw materials to manufacturers of consumer products. In addition, the company provides phytochemical reference standards and research and development services. ChromaDex distributes its TRU NIAGEN products directly to consumers through its proprietary e-commerce platform, TRUNIAGEN.com, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. With headquarters in Los Angeles, California, ChromaDex Corporation was founded in 1999.

Frequently Asked Questions

What is ChromaDex's ticker?

ChromaDex's ticker is CDXC

What exchange is ChromaDex traded on?

The company's shares trade on the NASDAQ stock exchange

Where are ChromaDex's headquarters?

They are based in Irvine, California

How many employees does ChromaDex have?

There are 51-200 employees working at ChromaDex

What is ChromaDex's website?

It is chromadex.com

What type of sector is ChromaDex?

ChromaDex is in the Healthcare sector

What type of industry is ChromaDex?

ChromaDex is in the Biotechnology industry

Who are ChromaDex's peers and competitors?

The following five companies are ChromaDex's industry peers:

- Celcuity

- Fate Therapeutics

- Lexicon Pharmaceuticals Inc

- Novus Therapeutics, Inc.

- FibroGen